OPINION ARTICLE

Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings [version 1; peer review: 2 approved]

Nurulamin M. Noor , Sarah L. Pett, Hanif Esmail, Angela M. Crook, Claire L. Vale, Matthew R. Sydes , Mahesh K.B. Parmar

Medical Research Council Clinical Trials Unit, University College London, London, WC1V6LJ, UK

V1 First published: 09 Sep 2020, 9:1109
<https://doi.org/10.12688/f1000research.26253.1>
Latest published: 23 Nov 2020, 9:1109
<https://doi.org/10.12688/f1000research.26253.2>

Abstract

Global health pandemics, such as coronavirus disease 2019 (COVID-19), require efficient and well-conducted trials to determine effective interventions, such as treatments and vaccinations. Early work focused on rapid sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequent *in-vitro* and *in-silico* work, along with greater understanding of the different clinical phases of the infection, have helped identify a catalogue of potential therapeutic agents requiring assessment.

In a pandemic, there is a need to quickly identify efficacious treatments, and reject those that are non-beneficial or even harmful, using randomised clinical trials. Whilst each potential treatment could be investigated across multiple, separate, competing two-arm trials, this is a very inefficient process. Despite the very large numbers of interventional trials for COVID-19, the vast majority have not used efficient trial designs.

Well conducted, adaptive platform trials utilising a multi-arm multi-stage (MAMS) approach provide a solution to overcome limitations of traditional designs. The multi-arm element allows multiple different treatments to be investigated simultaneously against a shared, standard-of-care control arm. The multi-stage element uses interim analyses to assess accumulating data from the trial and ensure that only treatments showing promise continue to recruitment during the next stage of the trial.

The ability to test many treatments at once and drop insufficiently active interventions significantly speeds up the rate at which answers can be achieved. This article provides an overview of the benefits of MAMS designs and successes of trials, which have used this approach to COVID-19. We also discuss international collaboration between trial teams, including prospective agreement to synthesise trial results, and identify the most effective interventions. We believe that international collaboration will help provide faster answers for

Open Peer Review

Approval Status

1

2

version 2

(revision)

23 Nov 2020

version 1

09 Sep 2020

[view](#)

[view](#)

1. **Cyrus Mehta** , Cytel Corporation, Cambridge, USA

2. **Dmitri Nepogodiev** , University of Birmingham, Birmingham, UK

Any reports and responses or comments on the article can be found at the end of the article.

patients, clinicians, and health care systems around the world, including for future waves of COVID-19, and enable preparedness for future global health pandemics.

Keywords

multi-arm, multi-stage, MAMS, adaptive, platform, trials, efficient, conduct, epidemic, pandemic, SARS-CoV-2, COVID-19, FAME, IPD, meta-analysis

This article is included in the **Emerging Diseases and Outbreaks** gateway.

This article is included in the **Coronavirus** collection.

Corresponding author: Mahesh K.B. Parmar (m.parmar@ucl.ac.uk)

Author roles: **Noor NM:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Pett SL:** Writing – Review & Editing; **Esmail H:** Writing – Review & Editing; **Crook AM:** Writing – Review & Editing; **Vale CL:** Writing – Review & Editing; **Sydes MR:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Parmar MKB:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: NMN, HE, AMC, CLV and MKBP declare no conflicts of interests relevant to this work. SLP reports grants from University of Minnesota in support of the ACTT trials, during the conduct of the study. MRS reports grants and non-financial support from Astellas, grants from Clovis, grants and non-financial support from Janssen, grants and non-financial support from Novartis, grants and non-financial support from Pfizer, grants and non-financial support from Sanofi, during the conduct of the study; personal fees from Lilly Oncology, personal fees from Janssen, outside of the submitted work.

Grant information: The authors received no specific funding for this work. NMN is supported by a Medical Research Council PhD Studentship from the Medical Research Council Clinical Trials Unit at University College London (MC_UU_171339). *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2020 Noor NM *et al.* This is an open access article distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Noor NM, Pett SL, Esmail H *et al.* **Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings [version 1; peer review: 2 approved]** F1000Research 2020, 9:1109 <https://doi.org/10.12688/f1000research.26253.1>

First published: 09 Sep 2020, 9:1109 <https://doi.org/10.12688/f1000research.26253.1>

Introduction

Global health pandemics pose many challenges, which require rapid clinical answers. There have been a growing number of global health emergencies caused by infectious diseases, including the novel coronaviruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)¹, and recent outbreaks of Ebola and Zika². These have all been associated with significant morbidity and mortality, and demanded urgent evaluation for treatments and development of vaccines. With increasing globalisation, similar challenges are likely to be encountered with further waves of these diseases, and further novel infectious pathogens entering the human population. There is therefore a need for more efficient, well-conducted, and collaborative clinical trials to provide answers for such pandemic settings.

From the outset of the coronavirus disease 2019 (COVID-19) pandemic, there has been an astounding pace of discovery to characterise this condition. Within months after the first widely-reported cases, the genomic structure of SARS-CoV-2 causing COVID-19 was identified and work initiated to explore downstream biology³. Accordingly, there are multiple potential interventions with plausible biological mechanisms that have been proposed and are under investigation for treatment or prevention of COVID-19^{4,5}.

Urgent need for clinical trial efficiency in a pandemic setting

SARS-CoV-2 exemplifies the typical challenges of highly infectious pathogens entering the human population for the first time, given that there were initially no approved treatments nor any available vaccines. There was a need for answers even more quickly from clinical trials. Both a need to identify effective treatments for those most vulnerable to COVID-19 and, equally important, to identify ineffective interventions early, in order to direct resources to the most promising interventions.

Researchers are generally aware of the potential biases from non-randomised trials and small, underpowered randomised controlled trials (RCTs)⁶, as well as the difficulties of interpreting non-controlled cohort studies⁷. However in a pandemic setting, particularly for a condition with high risks of morbidity and mortality, there is typically demand for early access to treatments with potential benefit - even in the absence of any compelling RCT data⁸.

A review by the National Academy of Science, Engineering and Medicine from the United States of America (USA), on the international response to the 2014 Ebola outbreak in West Africa, highlighted many apparent errors and lessons to be learned⁹. A key criticism was that small, underpowered clinical trials did not provide answers to help direct clinical care, nor did “compassionate use” trial programmes, since even if treatments were provided to large numbers of individuals, little sense of relative efficacy could be made in the absence of a comparative control arm¹⁰. Indeed, there was a widespread recognition of the need for randomisation to determine if interventions are effective or not in global health pandemics.

Efficiencies of MAMS platform designs to investigate multiple interventions

Each potential intervention for COVID-19 could be investigated across separate traditional two-arm, RCTs. This is, however, an inefficient process, particularly if, as expected, a large number of these interventions turn out to be clinically ineffective.

Unfortunately, the lessons from previous epidemics have not been widely applied to COVID-19. The use of efficient trial approaches have been the exception rather than the rule, with over 2,500 separate clinical trials registered for COVID-19 by 25 August 2020 on the World Health Organisation (WHO) International Clinical Trials Registry Platform (ICTRP)¹¹. A large number of these registrations are for small, underpowered trials using traditional non-adaptive designs, and this inefficiency has been compounded by many overlapping and competing trials seeking to answer the same clinical question¹².

Moreover, the inefficiencies of using multiple, classical, two-arm RCTs have been felt even more keenly during the COVID-19 pandemic, given the ability of such an infectious pathogen to rapidly overwhelm health service capacity. First, each two-arm trial has a separate control group, which is hugely inefficient given the large overall numbers of patients required; second, the choice of interventions to be tested is often based on very limited information, which will inevitably lead to a large number of ‘negative’ trials. Finally, as information emerges, further interventions demand evaluation immediately and setting up a separate, new trial is again hugely inefficient and time consuming.

There has been a growing recognition of the need to adopt efficient RCT approaches in pandemic settings¹³. Indeed, irrespective of the medical condition, whenever there are multiple interventions meriting further assessment, there has increasingly been a cultural shift away from two-arm RCTs, towards multi-arm designs¹⁴. A multi-arm, multi-stage (MAMS) platform design, provides a solution to many of the problems described and could be considered for evaluation of treatments or preventative strategies.

The multi-arm element allows multiple different interventions (comparisons) to be investigated simultaneously against a shared, standard-of-care control arm¹⁵. The shared control arm approach means that fewer patients are required overall compared with numerous, separate trials and allows for greater assignment of participants to receive comparison interventions.

The multi-stage element of a MAMS design uses interim analyses to assess accumulating data from the trial and ensure that only treatments showing promise continue to recruit new participants during the next stage of the trial. Whilst therapies showing a lack of sufficient benefit or, indeed, signals of real harm, have recruitment halted.

The ability to test many interventions at once and move recruitment away from insufficiently effective interventions, significantly speeds up the rate at which answers can be

achieved¹⁶. The design also ensures resource and funding are allocated to the most promising arms. Importantly, the MAMS platform allows new interventions to be rapidly added for assessment at any time, via an approved protocol amendment rather than by launching a new or competing trial. The selection of new intervention arms is based on a range of information, including promising data from laboratory, animal or human studies, as well as consideration of factors such as cost and wider availability of the intervention¹⁶.

Advantages of MAMS platform design in non-pandemic settings

The MAMS platform has been successfully implemented in non-pandemic settings. Whilst adaptive, platform approaches have increasingly been used across early-phase trials for drug screening programmes in industry¹⁷, uptake in the late-phase setting has been more gradual¹⁸.

The MAMS approach was perhaps first designed and applied in the late-phase setting to ovarian cancer in the ICON5 trial (NCT00011986)^{19,20}, where many design features were implemented for the first time, and numerous lessons learned were incorporated into the STAMPEDE trial (NCT00268476)²¹. STAMPEDE has utilised a MAMS platform approach to investigate potential treatments for prostate cancer. This trial has been running since 2005 and will address at least ten randomised treatment comparisons over 20 years (by 2025). In the past 15 years, results from STAMPEDE have contributed to three changes in standard-of-care for patients with prostate cancer²². Separate parallel-group, two-arm trials would have taken many decades to produce such results.

The MAMS platform approach changes the standard research question from a two-arm RCT of ‘does this intervention improve outcomes?’, to the more informative question ‘do any of these interventions, and any further new interventions identified, which need to be tested, improve outcomes?’. Given the need for speed and the large proportion of RCTs that do not show a new intervention is better than the control, we believe that this is a more relevant research question to ask – and potentially offers great utility for infectious diseases in pandemic settings.

Use of a MAMS platform approach for infectious disease pandemics

In recent years, it has been shown that the MAMS approach can also be applied in the fast-moving context of global health emergencies, and equally within resource-limited healthcare settings.

In the 2016 Ebola outbreak in West Africa, four potential treatments for Ebola were simultaneously investigated in the PALM trial (NCT03719586)²³, with two treatments being “dropped” following interim analysis and the two more effective treatments proceeding to a further next stage of recruitment²³. The PALM consortium demonstrated the ability of such modern RCTs to be rigorously conducted during infectious disease

outbreaks and importantly to deliver clinical answers in a timely fashion.

Many treatments and trials have been proposed and initiated for COVID-19, and the extensive, ongoing screening projects of new and re-purposed agents will likely lead to many more potential interventions that require evaluation in the near future. Commendable private-public collaborations, such as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), programme have been setup to develop and test interventions at much greater speed than typical development programmes²⁴. Using a MAMS platform design offers a very efficient way to assess these interventions in RCTs, in order to make progress as rapidly as possible²⁵.

Only a small number of trials have utilised a MAMS platform approach for COVID-19. However, the benefits of a co-ordinated and collaborative approach using an efficient platform design, are well illustrated by the RECOVERY trial (NCT04381936). RECOVERY, being co-ordinated from the United Kingdom (UK), initially started as a four-arm trial, with multiple further comparisons added to date. Recruitment was able to start within nine days of the protocol being finalised²⁶, and remarkably three research questions were answered - with over 12,000 participants recruited - within a period of just over 100 days. Most importantly this trial has provided convincing results to influence changes in clinical practice^{27,28}.

There are a number of further notable trials using a MAMS platform approach for patients with COVID-19. The SOLIDARITY master protocol (ISRCTN83971151) advocated and co-ordinated by the WHO and adopted across many individual countries. The ACTT-3 trial (NCT04492475) -- an international trial co-ordinated from the National Institute of Allergy and Infectious Diseases in the USA, initially starting as a three-arm trial. This builds on successes of the adaptive two-arm ACTT-1 trial (NCT04280705), which demonstrated improved time to recovery with remdesivir, an antiviral medication, when compared with placebo²⁹. The TACTIC-R (NCT04390464) and TACTIC-E (NCT04393246) trials are investigating repurposed and experimental immunomodulatory medications, respectively, for COVID-19 across the UK. In addition, the PRINCIPLE trial (ISRCTN86534580) has demonstrated that the MAMS platform can also be adopted for assessment of potential interventions in a primary care setting during a global health pandemic.

Whilst this article has focused on the MAMS platform approach, additional and complementary multi-arm approaches can be used, including multi-arm, multi-factorial designs - such as the REMAP-CAP trial (NCT02735707). Notably, factorial approaches can also be combined with MAMS designs. A multi-arm, multi-factorial design may offer particular benefits when assessing multiple combinations of interventions, as is typically the case for patients being treated in an intensive care environment.

Challenges of a MAMS platform approach for pandemic trials

An often highlighted challenge, especially for longer-lasting platform protocols, is the potential for standard-of-care to change during the course of the trial and implications of this for a MAMS design³⁰. Indeed, in the context of a fast-moving infectious disease pandemic, it is likely that usual or standard care will change based on interim analysis of comparison arms (and reporting) from the current trial, or from emerging data and findings of other research studies. However, there are now well-reported methods to overcome the challenges from changing standards of care in a MAMS design³¹. These solutions principally ensure comparison of interventions to participants recruited to a contemporary standard-of-care treatment arm, rather than comparison with participants receiving historical standard-of-care treatment.

Setting up and undertaking multi-national trials of any design in non-pandemic settings can offer considerable challenges³², and the difficulties may be an order of magnitude greater in a pandemic - given the speed needed to setup these trials. Challenges to consider include ensuring adequate funding, staffing, alignment of a single trial protocol to enable appropriate regulation, monitoring and oversight in each country, and logistical considerations, such as implementation of protocol amendments simultaneously across participating countries and sites. An additional challenge, which can be very difficult to predict, will be which countries are most likely to be affected by a pandemic and at what time they are most likely to be affected. The relative national incidence of a disease, and fluctuations in these numbers, will have a critical bearing on the ability to recruit into any pandemic trial. Moreover, different nations will have variable infrastructures in place to allow rapid setup of sites and ability to deliver RCTs efficiently, including crucial aspects such as rapid distribution of medications.

It is sobering to reflect that a likely major contributor to the speed of setup for RECOVERY was that this trial was taking place in one country and within one healthcare system - without the need to overcome multiple regulatory and administrative hurdles across multiple countries. The WHO SOLIDARITY trial approach likely offers the best practical solution around some of these challenges for multi-national trials - using a single overarching master protocol, with individual and separate trial registrations and delivery in each respective country.

Future horizons

An important future consideration is the need to collate and synthesise information from RCTs in order to derive maximum benefit for patients worldwide. Accordingly, there is

an urgent need for collaboration between trial teams, to ensure the most accurate and rapid reporting of findings.

This collaboration could be achieved using the prospective framework for adaptive meta-analysis (FAME), which has been successfully used to pool data across ongoing trials of prostate cancer³³, and helped facilitate the identification of patient subgroups for whom individual treatments may be most effective³⁴. In the COVID 19 setting, meta-analysis using individual participant data (IPD) may be key to delineating which treatment strategies are most effective in individual patients³⁵. Accordingly, extending the FAME approach, to include prospective agreement to share IPD from relevant trials, could reduce any potential delay to IPD meta-analysis. Irrespective of which method is used, these collaborative approaches enable rapid synthesis and reporting of all the evidence, providing a clear message to patients, clinicians and the wider public.

It is also clear that there is a need to be prepared for both further waves of COVID-19 and future potential global health pandemics. A key aspect of preparedness will be for trial organisations to pre-prepare MAMS protocols ready to implement at speed, ideally using a seamless phase two/three approach. Given the multiple potential vaccines under development for COVID-19³⁶, appropriate consideration should be given to the application of MAMS designs to preventative vaccine trials in the near future. Similarly to treatment trials, the WHO is commendably supporting global efforts for evaluation of multiple vaccines in a SOLIDARITY vaccine trial protocol³⁷.

Conclusion

There is an urgent need for reliable evidence in pandemic settings, as illustrated by the COVID-19 pandemic. Well conducted, adaptive platform trials utilising a MAMS approach, offer substantial advantages over multiple, separate, two-arm trials. Indeed, trials using efficient approaches have provided some of the rapid answers needed in the COVID-19 pandemic. However, these efficient trial approaches have been the exception rather than the rule. In this respect, an important consideration for the future will be for funders, regulators and other key stakeholders to prioritise more efficient trial designs. Focusing efforts on MAMS protocols in particular, with international collaboration between co-ordinating trial teams, and prospectively planned meta-analyses of emerging data, should lead to faster identification of effective therapies and vaccines. This should also contribute to faster answers for patients, clinicians, and health care systems around the world, including for future waves of COVID-19 and enable preparedness for future global health pandemics.

Data availability

No data is associated with this article.

References

1. Petersen E, Koopmans M, Go U, *et al.*: **Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics.** *Lancet Infect Dis.* 2020; S1473-3099(20)30648-4.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Khubchandani J, Jordan TR, Yang YT: **Ebola, zika, corona...what is next for our world?** *Int J Environ Res Public Health.* 2020; 17(9): 3171.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Andersen KG, Rambaut A, Lipkin WI, *et al.*: **The Proximal Origin of SARS-CoV-2.** *Nat Med.* 2020; 26(4): 450–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Stebbing J, Phelan A, Griffin I, *et al.*: **COVID-19: combining antiviral and anti-inflammatory treatments.** *Lancet Infect Dis.* 2020; 20(4): 400–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Riva L, Yuan S, Yin X, *et al.*: **Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.** *Nature.* 2020.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Djulbegovic B, Glasziou P, Chalmers I: **The importance of randomised vs non-randomised trials.** *Lancet.* 2019; 394(10199): 634–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Grein J, Ohmagari N, Shin D, *et al.*: **Compassionate Use of Remdesivir for Patients with Severe Covid-19.** *N Engl J Med.* 2020; 382(24): 2327–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Ellenberg SS: **Clinical trials in the time of a pandemic.** *Clin Trials.* 2020; 1740774520939871.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Keusch GT, McAdam K, Cuff PA, *et al.*: **Integrating clinical research into epidemic response: The Ebola experience.** National Academies Press. 2017.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Rojek A, Martin G, Horby PW: **Compassionate drug (mis)use during pandemics lessons for COVID-19 from 2009.** *BMC Med.* 2020; 18(1): 265.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. World Health Organization: **International Clinical Trials Registry Platform (ICTRP).** [cited 2020 Aug 25].
[Reference Source](#)
12. Kouzy R, Abi Jaoude J, Garcia Garcia CJ, *et al.*: **Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.** *JAMA Netw Open.* 2020; 3(7): e2015100.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Dean NE, Gsell PS, Brookmeyer R, *et al.*: **Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks.** *N Engl J Med.* 2020; 382(14): 1366–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Parmar MKB, Carpenter J, Sydes MR: **More multiarm randomised trials of superiority are needed.** *Lancet.* 2014; 384(9940): 283–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Parmar MKB, Sydes MR, Cafferty FH, *et al.*: **Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols.** *Clin Trials.* 2017; 14(5): 451–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Sydes MR, Parmar MKB, Mason MD, *et al.*: **Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.** *Trials.* 2012; 13: 168.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Morgan CC, Huyck S, Jenkins M, *et al.*: **Adaptive Design: Results of 2012 Survey on Perception and Use.** *Ther Innov Regul Sci.* 2014; 48(4): 473–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Bothwell LE, Avorn J, Khan NF, *et al.*: **Adaptive design clinical trials: A review of the literature and ClinicalTrials.gov.** *BMJ Open.* 2018; 8(2): e018320.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Royston P, Parmar MKB, Qian W: **Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer.** *Stat Med.* 2003; 22(14): 2239–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Copeland LJ, Bookman M, Trimble E: **Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.** *Gynecol Oncol.* 2003; 90(2 Pt 2): S1–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. James ND, Sydes MR, Clarke NW, *et al.*: **Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): A multi-arm, multistage randomized controlled trial.** *BJU Int.* 2009; 103(4): 464–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Parker CC, James ND, Brawley CD, *et al.*: **Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.** *Lancet.* 2018; 392(10162): 2353–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Mulangu S, Dodd LE, Davey RT, *et al.*: **A randomized, controlled trial of Ebola virus disease therapeutics.** *N Engl J Med.* 2019; 381(24): 2293–303.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. National Institutes of Health: **Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV).** 2020; [cited 2020 Aug 25].
[Reference Source](#)
25. Kaplan R, Maughan T, Crook A, *et al.*: **Evaluating many treatments and biomarkers in oncology: A new design.** *J Clin Oncol.* 2013; 31(36): 4562–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Wise J, Coombes R: **Covid-19: The inside story of the RECOVERY trial.** *BMJ.* 2020; 370: m2670.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. RECOVERY Collaborative Group: **Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report.** *N Engl J Med.* 2020; NEJMoa2021436.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Horby P, Mafham M, Linsell L, *et al.*: **Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multicentre, randomized, controlled trial.** *medRxiv.* 2020.
[Publisher Full Text](#)
29. Beigel JH, Tomashek KM, Dodd LE, *et al.*: **Remdesivir for the Treatment of Covid-19 — Preliminary Report.** *N Engl J Med.* 2020; NEJMoa2007764.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. Schiavone F, Bathia R, Letchmanan K, *et al.*: **This is a platform alteration: A trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.** *Trials.* 2019; 20(1): 264.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Attard G, Sydes MR, Mason MD, *et al.*: **Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.** *Eur Urol.* 2014; 66(5): 799–802.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Sydes MR, Egawa S, Sanders K, *et al.*: **Reflections on attempted Anglo-Japanese collaboration on STAMPEDE: A randomized controlled trial for men with prostate cancer.** *Int J Urol.* 2011; 18(8): 553–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Burdett S, Boevé LM, Ingleby FC, *et al.*: **Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis.** *Eur Urol.* 2019; 76(1): 115–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Vale CL, Fisher DJ, White IR, *et al.*: **What is the optimal systemic treatment of men with metastatic, hormone-naïve prostate cancer? A STOPCAP systematic review and network meta-analysis.** *Ann Oncol.* 2018; 29(5): 1249–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Tierney JF, Fisher DJ, Burdett S, *et al.*: **Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study.** *PLoS Med.* 2020; 17(1): e1003019.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Thanh Le T, Andreadakis Z, Kumar A, *et al.*: **The COVID-19 vaccine development landscape.** *Nat Rev Drug Discov.* 2020; 19(5): 305–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. World Health Organization (WHO): **An international randomised trial of candidate vaccines against COVID-19.** World Health Organization. 2020; [cited 2020 Aug 25].
[Reference Source](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 29 October 2020

<https://doi.org/10.5256/f1000research.28976.r73671>

© 2020 Nepogodiev D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Dmitri Nepogodiev

University of Birmingham, Birmingham, UK

The authors make a clear case for the benefits of adaptive platform trials in the context of the COVID-19 pandemic. The RECOVERY trial has demonstrated that MAMS design can significantly accelerate the rate at which urgent research questions can be robustly answered. However, even with the increased efficiency that MAMS offers, such platform trials still require large numbers of patients to be recruited. For example, RECOVERY has now recruited 15,000 patients but this has required concerted recruitment across most (n=176) UK hospitals. Realistically, during a pandemic it is only feasible for available local research infrastructure to support a limited number of such large-scale trials. This raises issues about how a consensus is reached on what trials are supported and what treatments they test.

1. What research questions should be addressed? There are a large number of research questions relating to SARS-CoV-2 across different domains (prophylaxis, treatment, public health measures etc), different patient groups, and different settings (primary care, acute hospitals, nursing homes etc). It is not feasible to support a large number of trials so research questions must be prioritised. Who should do this and on what basis?
2. Who should lead such trials? This requires multi-disciplinary (multi-institutional) teams with a track record of delivering large-scale studies. A pandemic is probably not the best time for novice trialists to get started.
3. For a treatment trial (e.g. RECOVERY) how should treatments be selected? Although a large number of potential repurposed treatments were proposed, there was relatively little early phase research to indicate which should go to phase III trials. So who should make these decisions and how?
4. New treatments are now being developed for COVID-19. How should a pipeline be set up linking phase II studies to the phase III platform trial to ensure that promising treatments seamlessly and efficiently progress?
5. Once the results for a trial arm have been analysed and final results are available how

should the results be disseminated? Should this be through the traditional peer review, pre-print servers, press release? How can research findings be rapidly linked in to clinical guidelines?

Although these points are beyond the specifics of the MAMS design, they are important to the overall aim of rapidly delivering impactful research during the pandemic and they are likely to be issues faced by anyone setting up a MAMS trial in this context. Perhaps a few brief comments on this might be interesting?

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Public health; epidemiology; surgery

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 17 Nov 2020

Nurulamin Noor, University College London, London, UK

We are grateful to both reviewers for their careful assessment of this manuscript, and their constructive comments.

We have provided a point-by-point response to each of the reviewers' comments below, added in citations to support the additional text, and where applicable updated current citations. The changes to the manuscript are described and, where applicable, added changes are highlighted as tracked changes in the revised manuscript.

Best wishes,

Reviewer: 2

Comment: The authors make a clear case for the benefits of adaptive platform trials in the context of the COVID-19 pandemic. The RECOVERY trial has demonstrated that MAMS

design can significantly accelerate the rate at which urgent research questions can be robustly answered.

Response: Thank you for your positive comments and for your careful consideration of this manuscript.

Comment: However, even with the increased efficiency that MAMS offers, such platform trials still require large numbers of patients to be recruited. For example, RECOVERY has now recruited 15,000 patients but this has required concerted recruitment across most (n=176) UK hospitals. Realistically, during a pandemic it is only feasible for available local research infrastructure to support a limited number of such large-scale trials. This raises issues about how a consensus is reached on what trials are supported and what treatments they test.

Response: Thank you for this question about prioritisation of trials in a pandemic. We agree that one of the benefits from using the MAMS platform protocol approach is the reduced competition between trials and greater efficiencies overall. We also agree that another source of efficiency will be from approaches where there are wide-scale support for fewer platforms rather than many overlapping and competing platforms. Ultimately, in a pandemic setting given the need for speed for answers, we believe the platforms, which can be setup at speed to start answering research questions are most likely to provide the answers needed. We have now included these above points in our discussion.

Comment: What research questions should be addressed? There are a large number of research questions relating to SARS-CoV-2 across different domains (prophylaxis, treatment, public health measures etc), different patient groups, and different settings (primary care, acute hospitals, nursing homes etc). It is not feasible to support a large number of trials so research questions must be prioritised. Who should do this and on what basis?

Comment: For a treatment trial (e.g. RECOVERY) how should treatments be selected? Although a large number of potential repurposed treatments were proposed, there was relatively little early phase research to indicate which should go to phase III trials. So who should make these decisions and how?

Comment: New treatments are now being developed for COVID-19. How should a pipeline be set up linking phase II studies to the phase III platform trial to ensure that promising treatments seamlessly and efficiently progress?

Response: Thank you for these three linked questions about selection of research questions and interventions within a MAMS platform protocol. We entirely agree that the MAMS platform can be used to evaluate a number of different interventions. To date, the majority of interventions that have been assessed have been investigational medicinal products (IMPs) for treatment. However, we strongly believe that non-IMP interventions also require assessment in a pandemic setting. The MAMS platform offers many benefits for evaluating prophylactic, treatment or preventative interventions. Ultimately the decision for which

interventions should be studied within a trial platform including future intervention arms, rest with the trial team itself. We have now included this in the discussion and about factors for trial teams to consider when adding in new intervention arms and assessing their progress.

Comment: Who should lead such trials? This requires multi-disciplinary (multi-institutional) teams with a track record of delivering large-scale studies. A pandemic is probably not the best time for novice trialists to get started.

Response: We thank the reviewer for this question and agree that given the complexities and workload associated with delivering MAMS platform trials, especially in the late-phase trial setting, these trials would likely be best delivered by multi-disciplinary organisations and teams with experience and track record in the area. We have included this in our discussion section and cited three citations further exploring MAMS platform trials from: a trial management perspective (Schiavone et al. Trials, 2019), a data management perspective (Hague et al. Trials, 2019), and from a trial team perspective for working within and delivering large MAMS platform trials in the late-phase trial setting (Morrell L et al. Trials, 2019).

Comment: Once the results for a trial arm have been analysed and final results are available how should the results be disseminated? Should this be through the traditional peer review, pre-print servers, press release? How can research findings be rapidly linked in to clinical guidelines? Although these points are beyond the specifics of the MAMS design, they are important to the overall aim of rapidly delivering impactful research during the pandemic and they are likely to be issues faced by anyone setting up a MAMS trial in this context. Perhaps a few brief comments on this might be interesting?

Response: Thank you for this question about the important topic of when and how to report findings from comparison intervention arms during the course of a MAMS platform. The challenge of rapid and appropriate dissemination is pertinent to all trials. In a MAMS platform trial where comparison arms will have primary results available at different times during the course of the platform, we strongly believe that primary outcome results from intervention arms should be reported as soon as these results have been analysed and are available - and that it would be unethical to delay reporting these findings until all comparison arms have primary results available. We support the process of traditional peer review but given the length of time that this can take, we also support appropriate use for earlier dissemination of headline findings such as through the use of open-access, pre-print reports. We have now included a section on this topic in the challenges section of our manuscript.

Competing Interests: None

<https://doi.org/10.5256/f1000research.28976.r71099>

© 2020 Mehta C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cyrus Mehta

Cytel Corporation, Cambridge, MA, USA

General Comments

This paper highlights the many benefits of designing a randomized clinical trial so that several treatment arms are compared in a pairwise fashion to a common control arm, with interim analyses to identify effective treatments and drop ineffective ones from further consideration. The considerable efficiency that such a design offers relative to the more conventional two-arm clinical trial arises in three ways. First, since many treatment arms share the same control arm, there is a saving of sample size. Second, the efficacy and/or futility data for each of the treatment interventions is obtained much earlier, and more reliably, than it would be were the interventions to be studied in separate two-arm trials that are conducted in sequence and with smaller sample sizes. Thirdly the operational infrastructure associated with setting up the multi-arm trial need only be created once, and can be used repeatedly, with minor adjustments, as current treatment arm exit the platform and new arms replace them. The references to on-going and completed trials, many of which are pandemic related, are a special strength of this paper.

The authors have also pointed some of the challenges of the MAMS platform approach. Much of this discussion relates to aligning the special requirements of participants from different countries and sites, with different medical needs, different treatment interventions and different funding sources and onto a single protocol. This is a vast problem that cannot be discussed adequately in a short survey paper. Perhaps it is worthwhile to mention in this context the EU-PEARL Consortium (eu-pearl.eu).

Issues in Need of Further Discussion:

1. **Changing the Control Arm.** How does one handle the problem of comparability if one of the interventions attains statistical and clinical significance at an interim analysis and thereby becomes the new control arm? Suppose, for example, that while subjects are still being followed, one of the arms attains statistical significance by crossing a group sequential boundary. Would you continue with the current SOC until the pre-specified follow-up of the remaining arms was completed? Would that be ethical? On the other hand, if you were to immediately replace the SOC with the new intervention, how would you interpret the results of a comparison to a control arm that was replaced in mid-stream?
2. **Concurrent Controls.** If one or more arms are dropped for futility and are replaced by new arms, what are your thoughts on using all the control-arm data in the comparison with the new arms, versus using only the concurrent control-arm data? Some Bayesian trials have used the former approach.
3. **Control of Multiplicity.** Multiplicity issues can arise if one performs repeated significance tests over time on a specific treatment arm to determine if it is efficacious. This source of multiplicity can be controlled by use of group-sequential efficacy boundaries. A different

source of multiplicity arises because multiple treatments are being tested in the same protocol. Therefore one must ask whether these treatments are members of one family or whether there is no relationship whatsoever between them, and they have merely been placed in the same protocol for the convenience of sharing a common control arm. In the former case the family-wise error rate must be controlled while in the latter case, only the pair-wise error rate must be controlled. Which type of control is more appropriate in the Covid setting? These are important conceptual issues that should be discussed.

4. **Adaptive Sample Size Re-assessment.** What are the authors' views on estimating the treatment effect at an interim analysis and adjusting the sample size based on the new evidence from the trial itself? Appropriate statistical methods are available to control the error rate in this situation. In a Covid setting, where very little is known about the efficacy of the treatment interventions, would it not be desirable to commit to a final sample size only after having observed a reasonable amount of data from the trial?

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: I am a biostatistician with expertise in design of adaptive clinical trials

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 17 Nov 2020

Nurulamin Noor, University College London, London, UK

We are grateful to both reviewers for their careful assessment of this manuscript, and their constructive comments.

We have provided a point-by-point response to each of the reviewers' comments below, added in citations to support the additional text, and where applicable updated current citations. The changes to the manuscript are described and, where applicable, added changes are highlighted as tracked changes in the revised manuscript.

Best wishes,

Reviewer: 1

Comment: This paper highlights the many benefits of designing a randomized clinical trial so that several treatment arms are compared in a pairwise fashion to a common control arm, with interim analyses to identify effective treatments and drop ineffective ones from further consideration. The considerable efficiency that such a design offers relative to the more conventional two-arm clinical trial arises in three ways. First, since many treatment arms share the same control arm, there is a saving of sample size. Second, the efficacy and/or futility data for each of the treatment interventions is obtained much earlier, and more reliably, than it would be were the interventions to be studied in separate two-arm trials that are conducted in sequence and with smaller sample sizes. Thirdly the operational infrastructure associated with setting up the multi-arm trial need only be created once, and can be used repeatedly, with minor adjustments, as current treatment arm exit the platform and new arms replace them. The references to on-going and completed trials, many of which are pandemic related, are a special strength of this paper.

Response: Thank you for your positive comments and for your careful reading of this manuscript.

Comment: The authors have also pointed some of the challenges of the MAMS platform approach. Much of this discussion relates to aligning the special requirements of participants from different countries and sites, with different medical needs, different treatment interventions and different funding sources and onto a single protocol. This is a vast problem that cannot be discussed adequately in a short survey paper. Perhaps it is worthwhile to mention in this context the EU-PEARL Consortium (eu-pearl.eu).

Response: We thank the reviewer for this suggestion and agree that these are important points that will likely be best considered by international collaborative efforts. We have now included reference to important international efforts in this regard, including mention of both the EU-PEARL Consortium and to the Clinical Trials Transformation Initiative (CTTI).

Comment: Changing the Control Arm. How does one handle the problem of comparability if one of the interventions attains statistical and clinical significance at an interim analysis and thereby becomes the new control arm? Suppose, for example, that while subjects are still being followed, one of the arms attains statistical significance by crossing a group sequential boundary. Would you continue with the current SOC until the pre-specified follow-up of the remaining arms was completed? Would that be ethical? On the other hand, if you were to immediately replace the SOC with the new intervention, how would you interpret the results of a comparison to a control arm that was replaced in mid-stream?

Response: Thank you for this question about change in standard of care for control arms. We certainly agree that in the context of a fast-moving infectious disease pandemic, it is

likely that usual or standard care will change based on interim analysis (and reporting) of comparison arms. We agree that it would be unethical to continue treating new patients with a historical standard of care in light of an evidence-based and available better standard of care, and have now made this clear in the discussion. We have also included about the need to compare comparison/intervention arms in a pairwise manner with the participants in the standard of care arm, at the time of enrolment. For ongoing patients in the trial when convincing results emerge, there would need to be careful consideration for each participant – the trial results apply to patients who meet the entry criteria and many ongoing participants may no longer be in this same state; this is more likely in trials and disease courses that run over a longer period.

Comment: Concurrent Controls. If one or more arms are dropped for futility and are replaced by new arms, what are your thoughts on using all the control-arm data in the comparison with the new arms, versus using only the concurrent control-arm data? Some Bayesian trials have used the former approach.

Response: Thank you for this challenging question on use of control data from trials. We agree that there has been variable practice across platform trials. Whilst some trials do use historical control group data from the entirety of a platform trial, we encourage applying caution, particularly in the late-phase trial setting, and when there are changes in standard of care for the control arm group within the course of a trial. Staying with the contemporaneously randomised patients is likely the better course of action in most instances.

Comment: Control of Multiplicity. Multiplicity issues can arise if one performs repeated significance tests over time on a specific treatment arm to determine if it is efficacious. This source of multiplicity can be controlled by use of group-sequential efficacy boundaries. A different source of multiplicity arises because multiple treatments are being tested in the same protocol. Therefore one must ask whether these treatments are members of one family or whether there is no relationship whatsoever between them, and they have merely been placed in the same protocol for the convenience of sharing a common control arm. In the former case the family-wise error rate must be controlled while in the latter case, only the pair-wise error rate must be controlled. Which type of control is more appropriate in the Covid setting? These are important conceptual issues that should be discussed.

Response: Thank you for this question about multiplicity, which is of interest to many of the authors. We have now included a short discussion about multiplicity and control of error rates when adding intervention arms in the context of a pandemic platform and added in a recent citation to support this text (Choodari-Oskoei et al. Clinical Trials, 2020).

Comment: Adaptive Sample Size Re-assessment. What are the authors' views on estimating the treatment effect at an interim analysis and adjusting the sample size based on the new evidence from the trial itself? Appropriate statistical methods are available to control the error rate in this situation. In a Covid setting, where very little is known about the efficacy of

the treatment interventions, would it not be desirable to commit to a final sample size only after having observed a reasonable amount of data from the trial?

Response: Carefully planned and explained adaptive sample size re-assessment could also be incorporated into a MAMS platform protocol. However, this is a controversial topic. We do advise an element of caution as with all adaptations made following interim analysis in terms of clarifying which individuals/committees have access to unblinded interim outcome data and pre-specifying how data will be used to inform decision-making. We note with interest that the RECOVERY trial - used as one of the exemplar trials in this manuscript - did not have an initial sample size calculation, and used data from early periods within the trial to allow subsequent sample size calculations. We have now accommodated this in the discussion section of the manuscript.

Competing Interests: None

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research